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MACROPHAGES BY TWO SEQUENTIAL LYMPHOKINE SIGNALS: INTERFERON-? 
We describe a new lymphokine activity, macro- 
phage cytotoxicity  inducing  factor 2 (MCIFP), in  the 
T cell  mitogen-induced  supernatant  of  a  murine T 
cell  clone in  long-term  culture. MCIF2 has the  fol- 
lowing  properties: 1) it elutes from a  Sephadex G- 
100 column in three m.w. forms (10, 34, and 100 
KD); 2) it is acid  labile (pH 2 to 4) and heat  sensitive 
(80 min at 56°C); 3) it is not  constitutively  secreted, 
coexists in  the  same  supernatant  with  immune  in- 
terferon (IFN-y), and synergizes with IFN--/ for  induc- 
tion of  tumoricidal  and  schistosomulicidal  resident 
peritoneal  mouse  macrophages. We uncoupled this 
synergy and show that IFN-y serves as the first 
("priming") and MCIF2 as the second ("triggering") 
signal  for  macrophage  activation.  Application of the
lymphokines in the  reverse  order  was  ineffective. 
These  data  demonstrate  a  two-step  mechanism of 
macrophage activation. 
Macrophages activated by T cell-derived lymphokines, 
called macrophage-activating  factors (MAF],3  play an  es- 
sential role in  the  defense  against  cancer  and infectious 
diseases ( 1 ,  2). MAF are a  heterogeneous group of lym- 
phokines and induce a variety of macrophage  functions 
(3-5). e.g., the killing of tumor cells and of schistosomula 
of Schistosoma rnansoni in vitro (3, 4, 6-8). 
Recently, immune  interferon (IFN-y) was  characterized 
as an important MAF in the  supernatant (SN) of normal 
and malignant T cells from mouse and  man (9-23). Mac- 
rophages  stimulated  with IFN-y increase the expression 
of Ia antigens on the cell membrane, show a higher 
oxidat.ive metabolism, and  inhibit  the r plication of intra- 
cellular  microorganisms (17. 20, 22, 23). IFN-y induces 
tumoricidal activity,  particularly of "elicited" macro- 
phages and  in  the presence of costimulators like lipopoly- 
saccharide (LPS) (9, 10,  15, 16). Activation of tumoricidal 
resident  peritoneal mouse macrophages by  IFN-y alone, 
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however, is suboptimal and variable (9, 10, 15, 16). or 
totally ineffective in LPS-low-responder mice (24). 
These  data  and  other data in  the  literature on non-IFN- 
7 MAF (25, 26) prompted us  to  investigate  whether  other 
T cell-derived lymphokines  in place of LPS and combined 
with IFN-7 can activate  macrophages. Our experiments 
showed synergy of  IFN-y and  another T cell-derived lym- 
phokine  for  induction of macrophage tumoricidal activ- 
ity. This lymphokine is secreted by normal T cells, long- 
term T cell clones, and T cell hybridomas and  was called 
macrophage cytotoxicity inducing factor 2 (MCIF2). In 
most cases MCIF2 coexisted with IFN-y in the S N  of T 
cells [ 1 6). 
In the experiments reported in this paper we show that 
MCIF2 in  the S N  of the long-term T cell clone 29  elutes 
from a  Sephadex G-100 column in  three m.w. forms (10 
kilodaltons [KD], 34 KD, and 100 KD), is acid labile, heat 
labile, and relatively alkaline  stable. In addition, we show 
the synergy of MCIF2 in  the IFN-y-depleted S N  of T cell 
clone 29 with IFN-r for activation of tumoricidal and 
schistosomulicidal mouse macrophages. Finally, we dem- 
onstrate  that activation of resident mouse macrophages 
occurs via a  two-step  mechanism with IFN-y as the  first 
and MCIFZ as the second signal. 
MATERIALS AND METHODS 
Mice. DBA/2 (H-2d) mice were obtained  from the  Zentralinstitut 
fur Versuchstiere,  Hannover. F.R.G. Mice of both sexes were  used 
for  experiments a t  6 to 8 wk  of age. 
Culture medium. Cells were cultured in RPMI 1640 (GIBCO Lab- 
oratories,  Grand Island, NY) supplemented with L-glutamine (2 mM 
final  concentration). streptomycin ( 1  00 Ggjml). and penicillin (1 00 
U/ml), HEPES buffer  (25 mM final  concentration),  2-mercaptoetha- 
no1 (lo-' M), and 10% fetal calf serum (FCS). 
T cell clone 29. The establishment. culture, and induction of 
lymphokine  secretion of T cell clone 29  has been  described (4, 16). 
Briefly, C57BL/6 mice were sensitized on the abdominal skin by 
2,4,6-trinitrophenyl chloride. Five days  later  the  draining axillary 
and  inguinal lymph node  cells  were  cultured  for 4 days. T cell clone 
29  was obtained by cloning these cells  in  limiting dilution microcul- 
tures.  The cells  from this clone grow adherent  to plastic. and  their 
growth is dependent on the presence  in the medium of interleukin 2 
(IL 2) from S N  of rat  spleen cells  stimulated by concanavalin A (Con 
A) for 24  to  48  hr. Lymphokine secretion was induced (after  washing 
the cells in IL 2-free  medium containing  2% FCS) by pulsing the cells 
Oxnard. CA) for 4 hr  with 10 Gam1 Con A, washing three  times  with 
in a large tissue culture flask (Falcon bottles, flat 3024F; Falcon. 
20 ml medium. and  culturing for 24  hr in medium free of both IL 2 
and Con A. After the  incubation,  the SN was  harvested, centrifuged, 
and stored at -20°C. Sham-induced S N  was prepared  without Con 
A stimulation. 
Several  additional IFN-y-positive control S N  from normal T cell 
clones,  induced  with Con A as described  above, were shown to be 
negative  for the lymphokine  synergizing with IFN-7 (16).  Further- 
A pulse induction, using trace-labeled Con A, was  less  than 0.01 
more, the maximal amount of Con A remaining in  the S N  after Con 
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pg/ml (27). Con A a t  a concentration of 1 pg/ml, however, did not 
induce macrophage activation  (data not shown). Therefore, a n  effect 
of Con A in our  experiments  on  induction of tumoricidal or schisto- 
somulicidal macrophages could be excluded. 
Depletion of T cell  clone 29 SN of IFN-7. T cell clone 29 S N  was 
depleted  from IFN-y  by solid-phase  absorption on  protein  A-Sepha- 
rose coupled with  the monoclonal hamster  anti-mouse IFN-y anti- 
body H22.1 (28). An equivalent of 1 ml slurry of Sepharose 4B was 
coupled by cyanogen bromide with 1 mg protein A (Pharmacia. 
Uppsala. Sweden)  (29). Protein  A-Sepharose (400 gl). diluted 1/15 in 
phosphate-buffered saline (PBS), was suspended in small plastic 
microtubes (Eppendorf No. 3810: Netheler and Hinz. Hamburg, 
F.R.G.). coated with  1% bovine serum  albumin (BSA), washed  with 
PBS, and  incubated  under  gentle  shaking  for 1 hr  at room tempera- 
ture with 1600 ng/tube H22.1 or control antibodies, respectively. 
After the  incubation,  the antibody-coupled  protein  A-Sepharose was 
washed twice with  culture medium and  2% FCS and used  for ab- 
sorption of prediluted  T cell clone 29 S N  a t  room temperature  under 
gentle  shaking  for 1 hr. S N  were harvested  after centrifugation of 
the  tubes  at  1600 x G for  10  min. UV light-sterilized, and used for 
macrophage activation. 
Column  chromatography of T cell  clone 29 SN. One milliliter of 
T cell clone 29 S N  was  chromatographed  on a 38 x 1.5 cm  Sephadex 
G-100  (Pharmacia. Uppsala, Sweden) column in PBS at a flow rate 
of 1.6 ml/hr. Human immunoglobulin G, BSA, and cytochrome c 
were  used as m.w. standards. One-milliliter fractions were collected, 
aliquoted, and tested for IFN-y and MAF activity. 
pH  and  temperature  sensitivity of MCIF2. Aliquots of 0.5 ml 
IFN-y-depleted T cell clone 29 S N  (4% v/v in  culture medium)  were 
dialyzed against  50 ml of different  buffers a t  pH 2,  4, 6, 8, and  10 
overnight.  The  same  samples were then dialyzed against 50 ml RPMI 
1640  for 4 hr. In addition, 0.5-1111 aliquots of IFN-y-depleted T cell 
clone 29 S N  were heated  for  10  to 80 min  at 56°C. Samples from 
both  treatments were  used as the second  signal.  together with IFN- 
y (16 U/ml) as the  first  signal, for  induction of macrophage tumor 
cytotoxicity. Untreated IFN-y-depleted T cell clone 29 S N  was used 
a s  a  control. 
Preparation of peritoneal  macrophages. Resident  macrophages 
were obtained  from  the peritoneal  cavity of mice. Macrophages  were 
enriched (>95%). as determined by uptake of carbon  particles  and 
by staining for nonspecific esterase (3), by adherence to culture 
plates. After 2 hr of adherence,  nonadherent cells  were removed and 
the viability of the remaining cells was determined (>95%). No 
lymphokines could be measured  in S N  from culture wells with plas- 
tic-adherent cells alone,  even  when  these cells  were stimulated  with 
Con A (1  6). 
tested  with  resident peritoneal macrophages (3 X IO5 cells/culture 
Macrophage tumor cytolysis. Macrophage tumor cytolysis was 
well) without addition of costimulators, e.g.,  LPS, except where 
indicated (LPS W. E. coli 0127:B8: Difco Laboratories, Detroit, MI). 
Macrophages  were incubated  in  100 pl culture medium in flat-bottom 
microtiter plates (Costar No. 3596; Costar, Cambridge, MA) for 24  hr 
with or without  MAF-containing  T cell clone 29 S N  and/or IFN-y. 
wells were refilled with  200 p1 medium, and 4 x lo4 6-[3H]thymidine 
After removal of the S N  and two washes of the cells, the  culture 
(3H-TdR)-labeled P815 (DBA/2 mastocytoma) target cells in 20 pl 
culture medium. The target  cells (1.5 X lo7 in 3 ml culture medium) 
were labeled with 0.2 ml 3H-TdR (5 Ci/mol.; Amersham Buchler, 
Braunschweig. F.R.G.) for  4 hr  at  37°C and  washed  three  times  in 
in  100 GI S N  after centrifugation of the cells a t  300 x G for 5 min. 
medium.  After 16 hr of incubation, 3H-TdR release  was determined 
Radioactivity was determined  in a beta counter. 
Percent specific 3H-TdR release was calculated by the  formula 
% Specific 3H-TdR release 
experimental cpm - control cpm 
maximum  cpm - control  cpm 1 x 100 
Experimental cprn are cprn released in wells containing activated 
macrophages and P815 tumor target cells; control cpm are cpm 
released from  P815  tumor  target cells cultured  with  nonactivated 
macrophages;  maximum cprn were cpm  from labeled P815  tumor 
target  cells (4 X lo4) released by lysis  with  Triton X-100 (5% v/v in 
and replicate  cpm  showed less  than 5% difference from the  mean. 
HzO). The control cpm were less  than 15% of the  maximum  cpm, 
Macrophage schistosomula killing. Schistosomula of Schisto- 
soma  mansoni  from a locally maintained Puerto  Rican strain (30) 
conditions described previously (31). The assay for schistosomula 
were  obtained in vitro by penetration of isolated mouse skin by using 
well) with  and without  MAF-containing  T cell clone 29 S N  and/or 
killing was performed by culturing macrophages (3 X 105/culture 
IFN-y. After 24 hr, the incubation medium was removed and re- 
placed by a schistosomula suspension  containing an average of 50 
larvae (effector to  target  ratio f 6000:l).  The viability of schistosom- 
ula  was visually determined after  48  hr of culture. Controls  were 
done with  schistosomula  incubated  with nonactivated  macrophages 
(3. 32). 
Macrophage  activation by sequential  lymphokine  signals. Mac- 
rophages (3 X 1 05/culture well) were incubated with medium (control) 
or lymphokines  for 15  hr, gently  washed twice, and  further  incu- 
bated with medium or lymphokines for 7 hr. After the  last  incuba- 
tion. the cells  were  gently  washed  once and tested for tumoricidal 
and schistosomulicidal  activity. 
IFN assay and  anti-IFN-y  antibodies. IFN was assayed by mea- 
suring  the reduction of the cytopathic  effect of vesicular stomatitis 
virus on L cells (4).  The IFN titer is expressed as the reciprocal of the 
highest serial twofold dilution of the  sample showing 50% reduction 
of the cytopathic  effect. A standard  reference mouse IFN-a/p (NIH 
standard G-002-904-511) was included in  each  assay. One unit (U) 
of  IFN in  the  assay  corresponds  to 1 U of the reference IFN. Recom- 
binant IFN-y (E. coli derived, 3 x lo7 U/mg protein, lot No. 2715/88. 
S 200, No. 3) was generously provided by Genentech, Inc.. San 
Francisco, CA). Protein A-binding, IFN-?-neutralizing monoclonal 
hamster anti-mouse IFN-y-antibodies have been described (28). 
H22.1 (purified  immunoglobulin) was generously provided by Dr. R. 
Schreiber,  Scripps Clinic, La Jolla. CA. 
RESULTS 
Macrophage activation by recombinant IFN-y and 
MCIF2 in  the SN of T cell  clone 29. Previous data sug- 
gested that IFN-y alone  was  insufficient  to  induce  acti- 
vation of resident peritoneal mouse macrophages to kill 
tumor cells and schistosomula of S. mansoni (4, 16, 24). 
Therefore, we postulated a second lymphokine (MCIF2) 
coexisting with IFN-7 in  T cell S N  that synergized with 
Thus, we compared the ability of recombinant IFN-7 
and of mitogen- and sham-induced S N  from long-term T 
cell clone 29 to activate tumoricidal and schistosomuli- 
cidal resident  peritoneal mouse macrophages.  The mito- 
gen-induced  T cell clone 29 S N  in  these  assays  was used 
at a concentration at which its antiviral titer corre- 
sponded to the  antiviral  titer of the recombinant IFN-y in 
the  same  test. Figure 1 shows  that  at  the concentration 
used,  recombinant IFN-y and sham-induced T cell clone 
29 S N  were inactive, whereas mitogen-induced T cell 
clone 29 S N  induced substantial macrophage activation 
in both tests.  This result is in line with the  literature  (4, 
9, 10, 16) and indicates  again that IFN-y alone is ineffec- 
tive to  activate  resident macrophages. It should be noted 
that  at higher  concentrations (>60 to 100 U/ml  IFN-y for 
macrophage  tumor cytotoxicity and >I30 to 1000 U/ml 
IFN-7 for macrophage schistosomula killing) recombi- 
nant IFN-y showed inconsistent  effects,  but  was  always 
negative at lower concentrations. 
In each  case, however, macrophage  activation could be 
achieved with low concentrations of IFN-y plus LPS. 
Under these conditions the levels of activity were similar 
to  those  obtained  with  T cell clone 29-derived S N  (Fig. 1). 
Taken  together, the above data  support  our previous 
findings and indicate that IFN-y in T cell clone 29 S N  
synergizes  with MCIF2 for  induction of tumoricidal and 
schistosomulicidal activity of resident peritoneal mouse 
macrophages. MCIF2 is not constitutively produced by T 
cell clone 29,  but induced to be secreted by the T cell 
mitogen Con A. 
IFN-7 (16). 
Macrophage activation by  the synergy of recornbi- 
nant IFN-7 and MCIF2 in the IFN-y-depleted T cell  clone 
29 SN. The  fact that MCIF2 coexists with IFN-y in  the S N  
of T cell clone 29 makes  its detection difficult. To more 
directly demonstrate  its  presence in further experiments. 
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and schistosomulicidal (B) resident peri- 
Figure 1.  Activation of tumoricidal (AI 
toneal mouse macrophages. Macrophages 
(3 X 106/culture) were incubated  with 
sham-induced T cell clone 29 S N  (M). 
(H). recombinant IFN-y (A- -A). re- 
mitogen-induced T cell clone 29 SN 
combinant IFN-y plus LPS (A- -A), and 
recombinant IFN-y plus  sham-induced T 
cell clone 29 SN (5% v/v in culture medium 
plus 2% FCS) (+- -.E). The concentration 
of the mitogen-induced T cell clone 29 S N  
was adjusted to a concentration a t  which 
its antiviral  titer corresponded  to the  an- 
tiviral titer of recombinant IFN-y in the 
same test.  After 24 hr  of incubation mac- 
rophage tumor cell and schistosomula 
Materfals and Methods.  Similar data 
killing was determined as described in 
were obtained in three separate experi- 
ments. 
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we used T cell clone 29 S N  depleted of IFN-y by solid- 
phase absorption  on  protein A-Sepharose coupled with 
the monoclonal anti-mouse IFN-y antibody H22.1 (H22.1 
antibodies were generously provided  by Dr. R. Schreiber, 
Scripps Clinic, La Jolla, CA). Table I shows  that IFN-y- 
depleted T cell clone 29 S N  devoid of any  measurable 
antiviral activity did not induce macrophage activity. 
MAF activity, however, was fully restored by adding  it  to 
the IFN-y-depleted S N  recombinant IFN--, a t  a concentra- 
tion that  was completely inactive by itself. As a result, 
the MAF activity of the IFN-y-depleted and  recombinant 
IFN-y-reconstituted T cell clone 29 S N  is comparable to 
that of the nondepleted SN. These  experiments demon- 
strate  that IFN-y and MCIF2 alone  are both  inactive for 
macrophage activation, but induce substantial activity 
when combined. 
Macrophage activation by two sequential lympho- 
kine  signals: IFN-y and MCIFB. The  results described in 
the previous section prompted us to investigate  whether 
the effects of IFN-y and MCIF2 could be uncoupled, and 
whether  macrophage  activation could be induced by se- 
quential lymphokine signals. Thus, resident peritoneal 
mouse  macrophages were incubated  with  lymphokines 
for 15  hr, washed, and again incubated with lympho- 
kines for 7 hr. After the second  incubation, the macro- 
TABLE I 
Activation of tumoricidal and  schistosomulicidal  resident  peritoneal 
mouse  macrophages by the  synergy of recombinant IFN-y and IFN-y- 
depleted T cell clone 29 SN 
Addltlon to 
Macrophage  Activity 
Culture Tumor cell killing Schlstosornuia  killing
I% %-TdR  releasel I% dead worms) 
Recombinant IFN-y" 8 
T cell clone 29 SNb 67.4 
T cell clone 29 SN. 0 
T cell clone 29 SN. 
IFN-y depleted' 
reconstituted  with 
IFN-y depleted and 
recombinant IFN- 
Yd 
68.3 
100 
3 
3 
98 
a Recombinant INF-y was used at  24 U/ml. 
Control (normal 1g)-absorbed T cell clone 29 S N  had  an IFN-y titer of 
24 U/rnl. 
IFN-y in T cell clone 29 S N  (used at  the  same concentration-4% v/v 
in medium-as in footnote b) was IFN-y depleted by absorption on the 
antiviral activity. 
monoclonal anti-IFN-y antibody H22.1. After  absorption, the S N  had no 
dIFN-y-depleted T cell clone 29 supernatant (as in footnote c) was 
reconstituted  with 24 U/ml recombinant IFN-y. Similar data were also 
obtained at  IFN-y titers of 6 or 12 U/ml and were confirmed in  three 
separate experfments. 
I I I I I I 
8 16 32 1 2  4 8 1 6 3 2  
IFN-T(UIml) 
SN CL 29 (%) 
2 4 8  0.25 0.5 1 2 4 8 
phages were washed and tested  for tumoricidal and  schis- 
tosomulicidal activity. The  lymphokines we used in  these 
experiments were recombinmt IFN-y, mitogen- and 
sham-induced  T cell clone 29 S N ,  and IFN-y-depleted T 
cell clone 29 S N  (devoid of antiviral  and MAF activity: see 
Table I). Mitogen-induced T cell clone 29 S N  as  the  first 
and second  signal  was used as a positive control  (data 
not  shown).  The  combination of recombinant IFN-y with 
recombinant IFN-y, or recombinant IFN--, with sham- 
induced  T cell clone 29 SN, respectively, used as either 
the first or the second signal was inactive (data not 
shown). Figure 2  shows that potent  macrophage  activa- 
tion was only observed when recombinant IFN-y was 
applied as the  first signal and MCIF2 in  the IFN-y-de- 
pleted T cell clone 29 S N  was applied as  the second signal. 
Incubation of macrophages  with  lymphokines in the re- 
verse order was ineffective. These data indicate that 
activation of tumoricidal and schistosomulicidal resident 
peritoneal mouse macrophages occurs via a two-step 
mechanism, with IFN-y as  the first signal and MCIF2 as 
the second signal. 
Physicochemical  characterization of MCIF2. For ini- 
tial biochemical characterization of MCIF2, T cell clone 
29 S N  was  chromatographed  on  Sephadex G-100. Each 
fraction  was  tested  for  antiviral activity in  the IFN assay 
and  at a  concentration of 10% (v/v in culture medium) 
for induction of macrophage  tumor cytotoxicity. Figure 3 
shows that IFN--, and MAF activity coeluted with a peak 
of activity at 34 KD (fractions 10 to 15). Again, this 
activity in  the MAF test  must have been due  to IFN--, plus 
MCIF2, because the highest concentration of IFN-7 in 
fraction 12 was only 4 U/mi, and recombinant IFN-y 
alone at 10 U/ml was  inactive. 
To test  whether IFN-y in amounts undetectable in the 
IFN assay  was  present in the column fractions before 
and  after  the IFN-y peak,  each  fraction  was  retested  with 
LPS (0.5 @/ml). No further MAF activity indicative for 
IFN-y could be detected by admixture of LPS. Retest of 
each  fraction, however, with  recombinant IFN-y (10 U/ 
ml) revealed two further  peaks of  MCIF2 at 10 KD (frac- 
tions 15 to 20)  and  100 KD (fractions 6 to 9). 
These  results are supported by the  data shown in Fig- 
ure  4.  The  fractions  under  each  peak  (peak I, fractions 7 
and 8; peak 11, fractions  11 to 14;  and peak 111, fractions 
16 to 18) were pooled, and  the pools were tested  either 
with or without recombinant IFN--/ (10 U/ml) for the 
induction of macrophage  tumor cytotoxicity. A s  expected, 
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IEPLETED 
and schistosomulicidal (€3) resident peri- 
Figure 2. Activation of tumoricidal (A) 
toneal  mouse  macrophages by two se- 
quential lymphokine signals. Macro- 
phages (3 x 105/culture) were incubated 
with culture medium. IFN-y-depleted T 
cell clone 29 S N  (see Materials  and  Meth- 
ods) (4% v/v in medium], or recombinant 
IFN-y (24 U/ml) for 15 hr (first signal) or 
7 hr (second signal), respectively. The 
macrophages  were  washed twice after  the 
first  and once after  the second incubation. 
After the last wash, macrophage tumor 
cetl and schistosomula killing was deter- 
mined as described in Materiafs  and 
Methods. Similar data were obtained  with 
6 and 12 U/ml IFN-y and confirmed in 
three  separate  experiments. 
(EDIUM IIFN- 7' L N -  ;T 4 ztc.t SN  CL 29 SN CL 29 DEPLETED ERETE SN CL 29 DEPLETE 
2. SIGNAL 7h \ 
F MCIFP IN T CELL  CLONE 29 SN loo KD 34KD 10 KD 
1 1 1 800 
700 
T cell clone 29 S N  was chromatographed 
Figure 3. MCIFZ in T cell clone 29 S N .  
on a Sephadex  G-100  column as described 
in Materials  and  Methods. Fractions 
were tested for antiviral (IFN-y) or MAF 
resident peritoneal  mouse  macrophages). 
activity  (induction of tumor cytotoxicity of 
In the MAF test,  the  fractions were tested 
at  a concentration of 10% (v/v in  culture 
medium] without any addition ( C - 0 )  or 
with the addition of LPS (0.5 pg/ml) 
( 0 - 0 )  or recombinant IFN-y (10 U/ml) 
(A--.-A]. The cpm for recombinant IFN- 
ground cpm of macrophages incubated 
y (m) or LPS alone were  within the  back- 
with culture medium alone. The shaded 
areas before and after the IFN-y peak 
[fraction 10 to 15) represent  the  increase 
in cpm in the MAF test induced by frac- 
tions  in  the  presence of recombinant IFN- 
y over cpm induced by fractions alone. 
The void volume of the column is also 
indicated. The IFN-y concentration of 
fraction 12. tested as 10% (v/v in  culture 
medium) in  the MAF test,  was 4 U/ml. 
4 
I 
t- 100 2.7 
2.6 
5 
IFN -# - VOID 10 15 20 FRACTIONS 1-IFN-y-1 
were used as the second signal,  together  with recombi- 
nant IFN-y as the first signal, to induce macrophage 
tumor cytotoxicity. Untreated IFN-y-depleted T cell clone 
29 S N  served as a control. The  results  summarized in 
Table I1 show that MCIF2 is acid labile (pH 2  to 4). stable 
at pH 8 and 10, and inactivated by heating for 80 min at 
56°C. 
DISCUSSION 
This paper  describes the biologic and initial biochemi- 
cal  characterization of MCIF2, a new lymphokine activ- 
ity, which plays a significant role in triggering of tumor- 
icidal and schistosomulicidal activity of IFN-y-primed 
resident  peritoneal mouse macrophages. We previously 
direct  activity  without IFN-y could only be  seen  with  the 
pool under peak I1 (34 KD), which  in  addition  to MCIF2 
primarily  contained IFN-y. Addition of recombinant IFN- 
y to this pool, therefore, did not  substantially  increase 
MAF activity. This  situation, however. was  different for 
the pool under  peak I11 (1 0 KD) and  under peak I (1 00 
KD). No MAF activity was  seen  without,  but  substantial 
activity was  seen  with,  recombinant IFN-y, inactive by 
itself. Thus, we conclude that MCIF2 activity  elutes in 
three  peaks  at 10, 34, and 100 KD. 
To determine the pH and temperature sensitivity of 
MCIF2, IFN-y-depleted T cell clone 29 S N  was dialyzed 
against  buffers  from pH 2 to 10 and heated for 10 to 80 
min at 56°C. respectively. Samples  treated  in  this way 
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PEAK n 7 PEAK l.U 
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macrophages by pools of fractions eluted from a Sephadex G- 100 column 
Figure 4. Induction of tumor cytotoxicity of resident  peritoneal mouse 
(see Fig. 3) without addition [NO ADD) or with  addition of recombinant 
and 8 (peak I). fractions  11 to 14  (peak 11). and  fractions  16 to 18 (peak 
IFN-y  (REC.  IFN-y) (10 U/ml). The  peaks  represent a p o l  of fractions 7 
IFN-y alone was  0.6% 3H-TdR release.  Sfmllar data were obtained in two 
111) (see Fig. 3). Peak I1 contains <4 U/ml IFN-7. The activity of recombinant 
separate experiments. 
TABLE I1 
Phqsicochernical  characteristics ofMCIF2 
Elution  from  Sephadex  G-100 10,  34,  100 KD 
pH sensitivitf Inactivated by pH 2 to 4 
Temperature sensitivitf inactivated by 80 min 
column" 
a t  56°C 
a The m.w. was determined by Sephadex  G-100 column chromatogra- 
phy of T cell clone 29 S N  as described in  the legend of Figure 3. 
blFN-y-depleted T cell clone 29 S N  (4% v/v in culture medium) as a 
source of  MCIF2 was used as the second  signal and recombinant IFN-y 
quots of IFN-7-depleted T cell clone 29 were dialyzed against  buffers at  
(16U/ml) a s  the  first signal to induce  macrophage tumor cytolysis. Ali- 
pH 2 to 10 overnight and 4 hr against RPMI 1640 as described in 
Materfats  and M e t h o d s .  Inhibition of 3H-TdR release  with the dialyzed 
2.60%; pH 4.73%; pH 6. 18%: pH 8.0%; pH 10.0%. 
samples  against  the nondialyzed MCIF2 control (35% 3H-TdR release): pH 
'MCIF2 was tested as described in footnote b. Aliquots of IFN-y- 
depleted T cell clone 29 S N  were heated for different times at  56°C. 
Inhibition of 3H-TdR release against  the nonheated MCIF2 control: 10 
min 56°C. 38%: 80 min 56% 70%. 
showed that IFN-y and MAF activities  in the S N  of short- 
term  T cell clones  in limiting  dilution  microcultures, long- 
term  T cell clones, and T cell hybridomas were not coor- 
dinately  expressed. S N  were  found  with low or  high an- 
tiviral and  the reverse MAF activity.  Similar data were 
obtained  in hybridoma S N  for the induction of macro- 
phage  schistosomulicidal  activity  (4). The MAF activity 
in such SN,  however, was completely inhibited by an  
antiserum raised  against  recombinant IFN-7.  Blocking of 
the MAF activity could be reversed by addition to the S N  
of recombinant IFN-y, inactive by itself (16). Taken to- 
gether,  these  data suggested to us  that IFN-y alone  was 
insufficient to induce tumoricidal activity of resident 
peritoneal  mouse  macrophages.  Therefore, we postulated 
a second lymphokine (MCIF2) coexisting with IFN-y in 
the T cell S N  that synergized with IFN-y. As this synergy 
was  also observed on the homogeneous cell population of 
the macrophage-like tumor PU 5- 1.8  (16), it was  evident 
that MCIF2 together  with IFN--/ stimulated  macrophages 
directly. 
Previous experiments  had  already  shown that MCIF2 
activity  was unlikely to be due  to a contamination of the 
T cell S N  with LPS (1 6). This is further made unlikely by 
the  fact  that  the combination of recombinant IFN-y with 
sham-induced  T cell clone 29 SN,  at a concentration (5%) 
at which the mitogen-induced T cell clone 29 S N  induced 
plateau macrophage activity,  was  inactive (Fig. 1). 
Meltzer (33) showed that activation of resident mouse 
macrophages proceeds in two steps, priming and trigger- 
ing, by stimulation  with two sequential lymphokine sig- 
nals (33). Subsequently, Schultz and Kleinschmidt (9). 
and Pace et al. (1 0) demonstrated that  the priming step 
was  due to the activity of IFN-y. The activity of IFN-y- 
primed macrophages could then be triggered by a second 
signal provided  by  LPS. We show  here that MCIF2 serves 
as a triggering signal for IFN-?-primed macrophages  with 
an efficiency that is comparable  to that of LPS. MCIF2 
may thus be the physiological second signal for activation 
of resident mouse macrophages. 
The  initial physiochemical characterization of MCIF2 
had to take  into  account hat activation of resident  mac- 
rophages could only be achieved by IFN--/ plus MCIF2. 
Therefore, we had  to  ascertain that we characterized the 
properties of  MCIF2 without interference from IFN-y. 
Sephadex G-100 column  chromatography of T cell clone 
29 SN revealed a 34-KD  IFN-y peak  with MAF activity. 
The MAF activity of this  peak, however. was  not  due to 
IFN-y alone,  because  recombinant IFN-y used at higher 
concentrations than  that of  IFN-y found  under that peak 
was inactive by itself. We concluded, therefore, that 
MCIF2 was also  found  under the IFN-y peak. Two addi- 
tional  peaks (1 0 KD and 100 KD)  of  MCIF2 activity were 
found in IFN-y-negative column fractions to which we 
admixed recombinant IFN-y. Thus, MCIF2 eluted from 
the column in three m.w. forms: 10, 34, and  100 KD. 
The higher m.w. forms may be aggregates of the lower 
ones, an observation that  is not uncommon for other 
lymphokines, e.g., lymphotoxin (34). Although we favor 
the idea that MCIF2 is a lymphokine distinct  from IFN-y, 
we cannot exclude that IFN-y has two different  sites, an 
antiviral  and a MAF site  (28). If this were the  case,  the 
10-KD form might be a  split product of IFN-+y with an 
inactive antiviral site not accessible to the anti-IFN-y 
monoclonal antibody H 22.1.  The  1 00-KD form might be 
an  aggregate of this 10-KD form. 
To evaluate the pH and temperature sensitivity of 
MCIF2, IFN-y-depleted T cell clone 29 S N  was dialyzed 
against  buffers at pH 2  to 10 or  heated for various  times 
at 56°C. Samples  with MCIF2 treated  in this way were 
compared with untreated MCIF2-containing, IFN-y-de- 
pieted T cell clone 29 S N  for their triggering activity on 
IFN-y-primed resident peritoneal mouse macrophages. 
MCIF2 proved to be acid labile, heat labile, and relatively 
stable at alkaline pH. 
Taken  together, our data determine MCIF2 as  a new 
lymphokine activity essential for triggering of IFN-y- 
primed macrophages. MCIF2 may be a new molecular 
species, but  our  present  data do  not exclude the pleio- 
tropic activity of a T cell-derived lymphokine that is 
already molecularly defined. In any  case,  the efficiency 
of macrophage  activation by the combination of IFN-+y 
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with MCIFP in vitro should also  initiate  experiments  to 
test the efficiency of such  combinations  in vivo. 
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